Abbott (NYSE: ABT) announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE